Novo Nordisk Ties Up With nference as Pediatric Semaglutide Data and FDA Label Changes Land in the Same Week
Published on 11/19/2026 at 07:12 | Editorial boerse-global.deNovo Nordisk closed out a busy stretch of pipeline and regulatory news with a strategic research partnership, announcing a collaboration with nference focused on cardiometabolic disease and healthy aging. The deal, disclosed by nference, will combine Novo Nordisk's clinical trial data with the AI specialist's technology and health-data network. Investors took it in stride rather than celebrating: the stock slipped 2.9% in the prior session and was down another 2.4% today.
The week's news flow was dense, and not all of it pointed the same direction. On the clinical side, Novo Nordisk on Monday published Phase 3 results from the STEP Young trial, which examined semaglutide in children aged six to under twelve with obesity. Mean BMI fell 17.4% over 68 weeks, compared with a 2.2% increase among placebo recipients. The findings appeared in The New England Journal of Medicine.
CagriSema Delivers Strong Weight Loss in REDEFINE 9
Earlier in the week, Novo Nordisk had already lifted the lid on REDEFINE 9, a Phase 3 study of its investigational CagriSema. Depending on the dose tested, estimated average weight loss reached 20.7% and 21.0% in the efficacy estimand, measured at 68 weeks. Placebo participants lost 2.0%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The company also moved on the filing front, submitting Etavopivat for approval in the US and Europe on 13 November. The drug candidate is being developed to treat sickle cell disease in patients aged twelve and older.
FDA Adds NAION Warning to GLP-1 Labels
Regulators, meanwhile, kept up the pressure. On 9 November the US Food and Drug Administration called for updated warnings on GLP-1 medicines, a group that includes Novo Nordisk's Ozempic and Wegovy. The labels will address NAION, a rare eye condition, and a possible risk of vision loss. The order covers other GLP-1 drugs beyond Novo's two products.
Novo Nordisk also used the week to relaunch NovoCare, a free support program for Wegovy. The offering bundles home delivery, a members' app and website, wellness partners and rewards.
Ad
Novo Nordisk Stock: New Analysis - 19 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
